Search - tctmd.com

Displaying 41 - 60 of 352

Sort: Relevancy | Date

Climbing Everest? Cardiac Arrhythmias Join Other Fabled Risks

News Daily News

Climbing Everest? Cardiac Arrhythmias Join Other Fabled Risks

Michael O'Riordan

April 04, 2024

LAAO Over Meds in AF? Demographic, Clinical Factors Are at Play

News Daily News

LAAO Over Meds in AF? Demographic, Clinical Factors Are at Play

March 15, 2024

Speedier Anticoagulation Reversal Tied to Better ICH Outcomes

News Conference News ISC 2024

Speedier Anticoagulation Reversal Tied to Better ICH Outcomes

February 15, 2024

News Daily News

Low Bleeding Profile With Asundexian Seen in Pooled Analysis

February 13, 2024

BMI Mostly Doesn’t Impact DOACs, Except Maybe at the Extremes

News Daily News

BMI Mostly Doesn’t Impact DOACs, Except Maybe at the Extremes

February 02, 2024

DOAC Don’ts New Review Clarifies When Not to Use Direct Oral Anticoagulants

News Daily News

DOAC Don’ts: New Review Clarifies When Not to Use Direct Oral Anticoagulants

January 17, 2024

Top Heart Rhythm News of 2023

News Daily News

Top Heart Rhythm News of 2023

December 26, 2023

AHA Selects 2023’s Leading Cardiovascular Research

News Daily News

AHA Selects 2023’s Leading Cardiovascular Research

December 22, 2023

New AF Guideline Emphasizes Early Rhythm Control, Elevates Ablation and LAAO

News Daily News

New AF Guideline Emphasizes Early Rhythm Control, Elevates Ablation and LAAO

November 30, 2023

Ischemic Stroke After LAA Closure May Be Less Severe Than on DOACs

News Daily News

Ischemic Stroke After LAA Closure May Be Less Severe Than on DOACs

Michael O'Riordan

November 27, 2023

Etripamil Nasal Spray Shows Promise for AF Patients With Rapid Ventricular Rate

News Conference News AHA 2023

Etripamil Nasal Spray Shows Promise for AF Patients With Rapid Ventricular Rate

November 16, 2023

The Artesia trial: Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation

Presentation AHA 2023

The Artesia trial: Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation

Presenter: Jeff Healey

November 16, 2023

AZALEA-TIMI 71: Abelacimab Slashes Bleeds vs Rivaroxaban in AF, but Stroke Impact Unclear

News Conference News AHA 2023

NOW PUBLISHED - AZALEA-TIMI 71: Bleeds Plunge With Abelacimab vs Rivaroxaban in AF, but Stroke Impact Unclear

November 12, 2023

ARTESiA: Apixaban Lowers Stroke Risk in Subclinical AF

News Conference News AHA 2023

ARTESiA: Apixaban Lowers Stroke Risk in Subclinical AF

November 12, 2023

Off-label DOAC Dosing Common in Hospitalized AF Patients, Too

News Conference News AHA 2023

Off-label DOAC Dosing Common in Hospitalized AF Patients, Too

November 07, 2023

Combined Surgical and Catheter Ablation Best for Persistent AF

News Conference News EACTS 2023

Combined Surgical and Catheter Ablation Best for Persistent AF

Michael O'Riordan

October 12, 2023

One-Third of Patients With AF After Surgery or Illness Have Recurrences

News Daily News

One-Third of Patients With AF After Surgery or Illness Have Recurrences

Michael O'Riordan

October 02, 2023

Etripamil Continues to Show Promise in Paroxysmal SVT: NODE-302

News Daily News

Etripamil Continues to Show Promise in Paroxysmal SVT: NODE-302

September 27, 2023

‘Overwhelming Reduction’ in Bleeding With Abelacimab vs Rivaroxaban in AF

News Daily News

‘Overwhelming Reduction’ in Bleeding With Abelacimab vs Rivaroxaban in AF

September 18, 2023

Prescribing a Generic for CVD? Plan, Drug Type, and Condition Impact Availability

News Daily News

Prescribing a Generic for CVD? Plan, Drug Type, and Condition Impact Availability

September 13, 2023

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.